Tim Lugo
Stock Analyst at William Blair
(1.90)
# 1,850
Out of 4,667 analysts
29
Total ratings
42.86%
Success rate
-8.68%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tim Lugo
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EYEN Eyenovia | Downgrades: Market Perform | n/a | $0.09 | - | 2 | Nov 15, 2024 | |
| BMRN BioMarin Pharmaceutical | Downgrades: Market Perform | n/a | $62.56 | - | 3 | Oct 30, 2024 | |
| RVNC Revance Therapeutics | Downgrades: Market Perform | n/a | $3.80 | - | 1 | Aug 12, 2024 | |
| APLT Applied Therapeutics | Initiates: Outperform | n/a | $9.43 | - | 1 | Jul 31, 2024 | |
| LENZ LENZ Therapeutics | Initiates: Outperform | n/a | $33.91 | - | 1 | Apr 15, 2024 | |
| SLDB Solid Biosciences | Initiates: Outperform | $40 | $4.96 | +706.45% | 1 | Mar 28, 2024 | |
| ZVRA Zevra Therapeutics | Initiates: Outperform | n/a | $8.97 | - | 1 | Mar 12, 2024 | |
| ABBV AbbVie | Upgrades: Outperform | n/a | $167.76 | - | 2 | Jan 29, 2024 | |
| ALLK Allakos | Upgrades: Outperform | n/a | $0.94 | - | 3 | Dec 18, 2023 | |
| ACRS Aclaris Therapeutics | Downgrades: Market Perform | n/a | $3.96 | - | 1 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $17.86 | - | 1 | Sep 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $13.55 | - | 2 | Sep 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.61 | - | 3 | Jul 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $62 | $4.91 | +1,162.73% | 1 | Jun 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $3.16 | - | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $39.34 | - | 1 | Jan 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $1.47 | - | 2 | Sep 22, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.04 | - | 1 | May 30, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $46 | $46.83 | -1.77% | 1 | May 30, 2017 |
Eyenovia
Nov 15, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $0.09
Upside: -
BioMarin Pharmaceutical
Oct 30, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $62.56
Upside: -
Revance Therapeutics
Aug 12, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $3.80
Upside: -
Applied Therapeutics
Jul 31, 2024
Initiates: Outperform
Price Target: n/a
Current: $9.43
Upside: -
LENZ Therapeutics
Apr 15, 2024
Initiates: Outperform
Price Target: n/a
Current: $33.91
Upside: -
Solid Biosciences
Mar 28, 2024
Initiates: Outperform
Price Target: $40
Current: $4.96
Upside: +706.45%
Zevra Therapeutics
Mar 12, 2024
Initiates: Outperform
Price Target: n/a
Current: $8.97
Upside: -
AbbVie
Jan 29, 2024
Upgrades: Outperform
Price Target: n/a
Current: $167.76
Upside: -
Allakos
Dec 18, 2023
Upgrades: Outperform
Price Target: n/a
Current: $0.94
Upside: -
Aclaris Therapeutics
Nov 13, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $3.96
Upside: -
Sep 21, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $17.86
Upside: -
Sep 20, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $13.55
Upside: -
Jul 22, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $2.61
Upside: -
Jun 16, 2021
Downgrades: Market Perform
Price Target: $62
Current: $4.91
Upside: +1,162.73%
Nov 24, 2020
Initiates: Outperform
Price Target: n/a
Current: $3.16
Upside: -
Jan 8, 2020
Initiates: Outperform
Price Target: n/a
Current: $39.34
Upside: -
Sep 22, 2017
Upgrades: Outperform
Price Target: n/a
Current: $1.47
Upside: -
May 30, 2017
Initiates: Outperform
Price Target: n/a
Current: $1.04
Upside: -
May 30, 2017
Initiates: Outperform
Price Target: $46
Current: $46.83
Upside: -1.77%